Clinical Trials Browser

NCT04978584 2026-04-15

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Phase 2 Active not recruiting

62 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04002947 2026-04-06

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

132 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04529772 2026-03-31

ESCALADE

Phase 3 Active not recruiting

611 enrolled

Lymphoid

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05256641 2026-03-10

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Phase 1/2 Recruiting

24 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05583149 2026-01-29

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Phase 2 Active not recruiting

28 enrolled 6 charts

Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT04604067 2025-12-30

Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Phase 2 Active not recruiting

260 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05952024 2025-12-22

ACRUE

Phase 2 Recruiting

80 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04257578 2025-10-08

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

Phase 1/2 Active not recruiting

23 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04546620 2025-08-06

REMoDL-A

Phase 2 Active not recruiting

453 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04189952 2025-05-31

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

Phase 2 Terminated

2 enrolled 6 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT02112526 2024-12-20

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Phase 1 Completed

21 enrolled 11 charts

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06441097 2024-06-04

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Phase 2 Not yet recruiting

152 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05820841 2023-08-31

ARCHED

Phase 3 Recruiting

330 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03899337 2023-01-09

STELLAR

Phase 2 Recruiting

105 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03527147 2022-08-15

PRISM

Phase 1 Completed

30 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04502394 2022-08-04

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Phase 1/2 Unknown

84 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03736616 2022-07-22

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Phase 2 Unknown

47 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse